Biotech ETF Rises 17% in a Month Without NVIDIA
A biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
During recessions, some index funds fare better than others. This intro highlights selection criteria and defensive positioning.
25,743 articlesA biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
As IPO activity spikes, investors wonder if history is rhyming with 1929 and 2000. This guide breaks down the signals...
Grocery prices are quietly reshaping how families spend and how lenders price risk. In this guide, learn why the next...
Pfizer stock is signaling a shift after years of underperformance. This article breaks down what’s changing, why it m...
A grounded, practical look at whether Micron Technology stock can move meaningfully in the next 12 months. Explore dr...
As Amazon prepares for its next earnings release, a provocative scenario targets Andy Jassy and AWS. This piece break...
May brings renewed focus on national security and market resilience. This guide identifies a top defense stock and sh...
New screenshots and text exchanges are at the center of a high-stakes custody dispute. This article breaks down what ...
A prominent wealth manager warns that baby boomers with heavy equity in 401(K)s may face a tougher retirement path if...
Markets edged lower in March as crypto regulation chatter intensified. Circle CRCL led the headlines with a sharp mov...
A data center spending surge across AI giants is reshaping markets. This article explains how a single company could ...
An emerging markets high dividend ETF is delivering a standout yield for income-focused investors, but the strategy c...